Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Telithromycin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 1.00 |
| ▸ | CYP3A5 | P20815 | 6/20 | 1.00 |
| ▸ | CYP3A7 | P24462 | 6/20 | 1.00 |
| ▸ | CYP3A43 | Q9HB55 | 6/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 4/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 1.00 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 1.00 |
| ▸ | GNRHR | P30968 | 2/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.51 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.51 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.51 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Telithromycin SCHEMBL19518975 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP3A5CYP3A7CYP3A43KCNH2 | |
| Telithromycin SCHEMBL14521662 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP3A5CYP3A7CYP3A43KCNH2 | |
| Telithromycin SCHEMBL784845 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP3A5CYP3A7CYP3A43KCNH2 | |
| Telithromycin SCHEMBL18035669 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP3A5CYP3A7CYP3A43KCNH2 | |
| Telithromycin SCHEMBL12858721 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP3A5CYP3A7CYP3A43KCNH2 | |
| Telithromycin SCHEMBL14268636 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP3A5CYP3A7CYP3A43KCNH2 | |
| Telithromycin SCHEMBL10819900 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP3A5CYP3A7CYP3A43KCNH2 | |
| Telithromycin SCHEMBL15387603 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP3A5CYP3A7CYP3A43KCNH2 | |
| Telithromycin SCHEMBL5100 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP3A5CYP3A7CYP3A43KCNH2 | |
| Telithromycin SCHEMBL31576166 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP3A5CYP3A7CYP3A43KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130095505-A1 | DETECTION OF LIPID OXIDISING ABZYMES IN SAMPLES | CAMBRIDGE THERANOSTICS LIMITED (GB) | 2013-04-18 | — | — | US | claimed |
| US-7939275-B2 | Methods for detection of chlamydia in samples | CAMBRIDGE THERANOSTICS LIMITED (GB) | 2011-05-10 | — | — | US | claimed |
| US-20090029395-A1 | Methods for Detection of Chlamydia in Samples | CAMBRIDGE THERANOSTICS LIMITED (GB) | 2009-01-29 | — | — | US | claimed |
| US-20080248505-A1 | Detection of Lipid Oxidising Abzymes in Samples | CAMBRIDGE THERANOSTICS LIMITED (GB) | 2008-10-09 | — | — | US | claimed |
| EP-1859275-A1 | METHODS FOR DETECTION OF CHLAMYDIA IN SAMPLES | Cambridge Theranostics Limited (GB) | 2007-11-28 | — | — | EP | claimed |
| EP-1859276-A1 | DETECTION OF LIPID OXIDISING ABZYMES IN SAMPLES | Cambridge Theranostics Limited (GB) | 2007-11-28 | — | — | EP | claimed |
| WO-2006090162-A1 | METHODS FOR DETECTION OF CHLAMYDIA IN SAMPLES | CAMBRIDGE THERANOSTICS LIMITED (GB) | 2006-08-31 | — | — | WO | claimed |
| WO-2006090164-A1 | DETECTION OF LIPID OXIDISING ABZYMES IN SAMPLES | CAMBRIDGE THERANOSTICS LIMITED (GB) | 2006-08-31 | — | — | WO | claimed |
| EP-3675838-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | Puretecch LYT, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| EP-3655104-A1 | AN OSTEOADSORPTIVE FLUOROGENIC SUBSTRATE OF CATHEPSIN K FOR IMAGING OSTEOCLAST ACTIVITY AND MIGRATION | The Regents of the University of California (US) | 2020-05-27 | — | — | EP | disclosed |
| WO-2019046491-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | ARIYA THERAPEUTICS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| WO-2019018238-A1 | AN OSTEOADSORPTIVE FLUOROGENIC SUBSTRATE OF CATHEPSIN K FOR IMAGING OSTEOCLAST ACTIVITY AND MIGRATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-01-24 | — | — | WO | disclosed |
| EP-3344325-A1 | LOCAL ADMINISTRATION OF DRUGS FOR THE TREATMENT OF ASTHMA | Mercator Medsystems, Inc. (US) | 2018-07-11 | — | — | EP | disclosed |
| EP-3240800-A1 | CLOSTRIDIUM DIFFICILE TARGETING MOIETIES AND CONSTRUCTS COMPRISING SAID MOIETIES | C3 JIAN, LLC (US) | 2017-11-08 | — | — | EP | disclosed |
| US-20090029395-A1 | Methods for Detection of Chlamydia in Samples | CAMBRIDGE THERANOSTICS LIMITED (GB) | 2009-01-29 | — | — | US | disclosed |
| US-20080248505-A1 | Detection of Lipid Oxidising Abzymes in Samples | CAMBRIDGE THERANOSTICS LIMITED (GB) | 2008-10-09 | — | — | US | disclosed |
| EP-1859275-A1 | METHODS FOR DETECTION OF CHLAMYDIA IN SAMPLES | Cambridge Theranostics Limited (GB) | 2007-11-28 | — | — | EP | disclosed |
| EP-1859276-A1 | DETECTION OF LIPID OXIDISING ABZYMES IN SAMPLES | Cambridge Theranostics Limited (GB) | 2007-11-28 | — | — | EP | disclosed |
| WO-2006090162-A1 | METHODS FOR DETECTION OF CHLAMYDIA IN SAMPLES | CAMBRIDGE THERANOSTICS LIMITED (GB) | 2006-08-31 | — | — | WO | disclosed |
| WO-2006090164-A1 | DETECTION OF LIPID OXIDISING ABZYMES IN SAMPLES | CAMBRIDGE THERANOSTICS LIMITED (GB) | 2006-08-31 | — | — | WO | disclosed |